Outlook Therapeutics (OTLK) Debt to Equity: 2015-2020
Historic Debt to Equity for Outlook Therapeutics (OTLK) over the last 4 years, with Jun 2020 value amounting to $0.05.
- Outlook Therapeutics' Debt to Equity rose 104.82% to $0.05 in Q2 2020 from the same period last year, while for Jun 2020 it was $0.05, marking a year-over-year increase of 104.82%. This contributed to the annual value of -$0.42 for FY2019, which is 6379.60% down from last year.
- According to the latest figures from Q2 2020, Outlook Therapeutics' Debt to Equity is $0.05, which was up 4,067.35% from -$0.00 recorded in Q1 2020.
- Outlook Therapeutics' 5-year Debt to Equity high stood at $0.48 for Q2 2016, and its period low was -$1.03 during Q2 2019.
- In the last 3 years, Outlook Therapeutics' Debt to Equity had a median value of -$0.31 in 2019 and averaged -$0.34.
- Per our database at Business Quant, Outlook Therapeutics' Debt to Equity plummeted by 6,379.60% in 2019 and then surged by 104.82% in 2020.
- Quarterly analysis of 5 years shows Outlook Therapeutics' Debt to Equity stood at -$0.23 in 2016, then plummeted by 109.45% to -$0.49 in 2017, then rose by 29.42% to -$0.35 in 2018, then spiked by 99.65% to -$0.00 in 2019, then skyrocketed by 104.82% to $0.05 in 2020.
- Its Debt to Equity was $0.05 in Q2 2020, compared to -$0.00 in Q1 2020 and -$0.00 in Q4 2019.